(Q34973874)

5 August 2017

1 reference

title

Glucocorticoids and treatment of prostate cancer: a preclinical and clinical review (English)

1 reference

5 August 2017

1 reference

Marwan Fakih

1

1 reference

5 August 2017

Candace S Johnson

series ordinal

2

1 reference

5 August 2017

Donald L Trump

series ordinal

3

1 reference

5 August 2017

language of work or name

English

0 references

publication date

1 October 2002

1 reference

5 August 2017

1 reference

5 August 2017

60

1 reference

5 August 2017

4

1 reference

5 August 2017

553-561

1 reference

Glucocorticoid induced apoptosis in leukemia.

5 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901741-7

7 January 2021

Glucocorticoids induce apoptosis in acute myeloid leukemia cell lines with A t(8;21) chromosome translocation

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901741-7

7 January 2021

Differential effects of androgens and glucocorticoids on regulation of androgen receptor concentrations and cell growth

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901741-7

7 January 2021

Testosterone levels in men with chronic obstructive pulmonary disease with or without glucocorticoid therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901741-7

7 January 2021

Reduction of serum testosterone levels during chronic glucocorticoid therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901741-7

7 January 2021

Androgen suppression by hydrocortisone without aminoglutethimide in orchiectomised men with prostatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901741-7

7 January 2021

Treatment of metastatic prostatic cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901741-7

7 January 2021

Lipocortin-derived peptides

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901741-7

7 January 2021

Lipocortin-1: cellular mechanisms and clinical relevance

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901741-7

7 January 2021

Lipocortin 1 and the control of cPLA2 activity in A549 cells. Glucocorticoids block EGF stimulation of cPLA2 phosphorylation

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901741-7

7 January 2021

Lipocortin-1 and the control of arachidonic acid release in cell signalling. Glucocorticoids (changed from glucorticoids) inhibit G protein-dependent activation of cPLA2 activity

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901741-7

7 January 2021

Glucocorticoid receptor function possibly modulates cell-cell interactions in osteoblastic metastases on rat skeleton

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901741-7

7 January 2021

Elevation of serum levels of urokinase-type plasminogen activator and its receptor is associated with disease progression and prognosis in patients with prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901741-7

7 January 2021

Urokinase-type plasminogen activator binding to its receptor stimulates tumor cell migration by enhancing integrin-mediated signal transduction

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901741-7

7 January 2021

Plasminogen activator system modulates invasive capacity and proliferation in prostatic tumor cells

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901741-7

7 January 2021

An amino-terminal fragment of urokinase isolated from a prostate cancer cell line (PC-3) is mitogenic for osteoblast-like cells

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901741-7

7 January 2021

Potential mechanism for the effects of dexamethasone on growth of androgen-independent prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901741-7

7 January 2021

Therapeutic potential of inhibition of the NF-kappaB pathway in the treatment of inflammation and cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901741-7

7 January 2021

Androgen and glucocorticoid receptor heterodimer formation. A possible mechanism for mutual inhibition of transcriptional activity

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901741-7

7 January 2021

Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901741-7

7 January 2021

Cortisone treatment in advanced carcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901741-7

7 January 2021

Use of dexamethasone for ureteric obstruction in advanced prostate cancer: percutaneous nephrostomies can be avoided

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901741-7

7 January 2021

A phase II randomized trial of megestrol acetate or dexamethasone in the treatment of hormonally refractory advanced carcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901741-7

7 January 2021

Evaluation of prostate-specific antigen as a surrogate marker for response of hormone-refractory prostate cancer to suramin therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901741-7

7 January 2021

Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901741-7

7 January 2021

Effect of prednisone on prostate-specific antigen in patients with hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901741-7

7 January 2021

Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901741-7

7 January 2021

Prostate specific antigen levels and clinical response to low dose dexamethasone for hormone-refractory metastatic prostate carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901741-7

7 January 2021

Prospective evaluation of hydrocortisone and suramin in patients with androgen-independent prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901741-7

7 January 2021

Hormone/antihormone withdrawal and dexamethasone for hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901741-7

7 January 2021

Dexamethasone does not significantly contribute to the response rate of docetaxel and estramustine in androgen independent prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901741-7

7 January 2021

Low doses of oral dexamethasone for hormone-refractory prostate carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901741-7

7 January 2021

Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901741-7

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901741-7

7 January 2021

Suramin therapy for patients with symptomatic hormone-refractory prostate cancer: results of a randomized phase III trial comparing suramin plus hydrocortisone to placebo plus hydrocortisone

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901741-7

7 January 2021

Flutamide versus prednisone in patients with prostate cancer symptomatically progressing after androgen-ablative therapy: a phase III study of the European organization for research and treatment of cancer genitourinary group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901741-7

7 January 2021

10.1016/S0090-4295(02)01741-7

Identifiers

DOI

1 reference

5 August 2017

1 reference